Nine Masts Capital’s Coherus Oncology CHRS Stock Holding History

Nine Masts Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,018	Closed	-$38.9K	–	192
2026 Q1	$38.9K	Buy	+23,018	New	+$40.9K	0.01%	185

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Nine Masts Capital's CHRS Position: Q2 2026 in Review

Nine Masts Capital sold out of Coherus Oncology (CHRS) in Q2 2026, closing a stake of 23,018 shares — an estimated $38.9K sold.

Nine Masts Capital first reported a position in CHRS in Q1 2026 and held it in 1 quarter. The position peaked at $38.9K in Q1 2026. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

Nine Masts Capital reported no remaining Coherus Oncology position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 23,018 Coherus Oncology shares in Q2 2026, an estimated $38.9K.
Nine Masts Capital first reported a position in Coherus Oncology in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's Coherus Oncology position peaked at $38.9K in Q1 2026.
147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.